arrow
P

Paul Fields

tempus labs
H指数:28
被引数:4,435

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cancer-specific T cell receptor discovery using 150,000 clinical genomics samples

利用15万临床基因组样本进行癌症特异性T细胞受体发现

2026-01-010
PRE
Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels

在个人和人群水平上对SARS-CoV-2感染的T细胞反应的大小和动态

2025-01-070
OAAI
COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort
2024-06-140
OAAI
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
2023-04-0345
PRE
Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy
2023-04-0133
OAAI
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
2022-01-2710
OAAI
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire

AZD1222/ChAdOx1 nCoV-19疫苗接种可诱导具有多种TCR库的多功能刺突蛋白特异性TH1反应

2021-11-1767
OAAI
Pre-transplant T-cell Clonality An Observational Study of a Biomarker for Prediction of Sepsis in Liver Transplant Recipients

移植前T细胞克隆性预测肝移植受者败血症的生物标志物的观察性研究

2021-06-165
OA
T cell fraction impacts oncologic outcomes in human papillomavirus associated oropharyngeal squamous cell carcinoma

T细胞分数影响人乳头瘤病毒相关口咽鳞状细胞癌的肿瘤学结局

2020-12-019
PREAI
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence (vol 1, pg 197, 2020)

原发性黑色素瘤T细胞的分子分析确定有转移复发风险的患者 (第1卷,197页,2020)

2020-03-170
OAAI
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence

原发性黑色素瘤T细胞的分子分析可确定有转移复发风险的患者

2020-01-2024
OAAI
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Pembrolizumab联合溶瘤病毒Pelareorep和化疗治疗晚期胰腺癌患者: Ib期研究

2020-01-03124
OAAI